Home » Stocks » PHAR

Pharming Group N.V. (PHAR)

Stock Price: $14.16 USD -0.44 (-3.01%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 9.03B
Revenue (ttm) 189.91M
Net Income (ttm) 40.67M
Shares Out 638.06M
EPS (ttm) 0.61
PE Ratio 23.34
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $14.16
Previous Close $14.60
Change ($) -0.44
Change (%) -3.01%
Day's Open 14.43
Day's Range 13.97 - 14.50
Day's Volume 7,772
52-Week Range 13.97 - 16.70


Hide News
PR Newswire - 1 month ago

Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") u...

PR Newswire UK - 1 month ago

Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unm...

SEC - 1 month ago

Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.

About PHAR

Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as ... [Read more...]

Research and Development in Biotechnology
Sijmen de Vries
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, Pharming Group's revenue was 169.02 million, an increase of 25.08% compared to the previous year's 135.13 million. Earnings were 36.20 million, an increase of 44.82%.

Financial numbers in millions EUR.
Financial Statements